ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
38.18
-0.13%
US Tech 100
19,448.00
-0.67%
S&P 500
5,739.81
-0.10%
US Dollar vs CAD
1.35218
0.33%
Bitcoin
65,745.82
0.86%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. PAVmed Inc (PAVM)

  7. PAVmed Inc (PAVM) News

PAVM

PAVmed (PAVM)

PAVmed Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PAVM
DateTimeSourceHeadlineSymbolCompany
09/24/20247:01AMPR Newswire (US)American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer TestNASDAQ:PAVMPAVmed Inc
09/16/20243:30PMPR Newswire (US)PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing RequirementsNASDAQ:PAVMPAVmed Inc
09/10/20246:56AMPR Newswire (US)Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World CongressNASDAQ:PAVMPAVmed Inc
09/03/20246:51AMPR Newswire (US)Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile HealthNASDAQ:PAVMPAVmed Inc
08/20/20247:16AMPR Newswire (US)Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and CancerNASDAQ:PAVMPAVmed Inc
08/13/20247:18AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PAVMPAVmed Inc
08/13/20247:16AMPR Newswire (US)The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal CancerNASDAQ:PAVMPAVmed Inc
08/13/20247:01AMPR Newswire (US)PAVmed Provides Business Update and Second Quarter 2024 Financial ResultsNASDAQ:PAVMPAVmed Inc
08/12/20243:08PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PAVMPAVmed Inc
08/12/20247:07AMPR Newswire (US)Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial ResultsNASDAQ:PAVMPAVmed Inc
08/08/20247:31AMPR Newswire (US)Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing EventNASDAQ:PAVMPAVmed Inc
08/06/20247:15AMPR Newswire (US)Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer TestingNASDAQ:PAVMPAVmed Inc
08/05/20247:15AMPR Newswire (US)Lucid Diagnostics to Participate in Upcoming Investor ConferencesNASDAQ:PAVMPAVmed Inc
07/30/20247:15AMPR Newswire (US)PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024NASDAQ:PAVMPAVmed Inc
07/29/20247:15AMPR Newswire (US)Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024NASDAQ:PAVMPAVmed Inc
07/23/20247:01AMPR Newswire (US)Lucid Diagnostics Announces Record Quarterly EsoGuard® Test VolumeNASDAQ:PAVMPAVmed Inc
07/11/20247:31AMPR Newswire (US)Lucid Diagnostics Launches New Corporate WebsiteNASDAQ:PAVMPAVmed Inc
07/02/20246:55AMPR Newswire (US)Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening PopulationNASDAQ:PAVMPAVmed Inc
06/13/20246:58AMPR Newswire (US)PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstituteNASDAQ:PAVMPAVmed Inc
06/12/20247:05AMPR Newswire (US)4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer TestingNASDAQ:PAVMPAVmed Inc
05/13/20247:43PMPR Newswire (US)PAVmed Provides Business Update and First Quarter 2024 Financial ResultsNASDAQ:PAVMPAVmed Inc
05/13/20247:00AMPR Newswire (US)Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial ResultsNASDAQ:PAVMPAVmed Inc
05/09/20246:49AMPR Newswire (US)Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA RecallNASDAQ:PAVMPAVmed Inc
05/07/20246:39AMPR Newswire (US)Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of DirectorsNASDAQ:PAVMPAVmed Inc
05/03/20247:35AMPR Newswire (US)PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024NASDAQ:PAVMPAVmed Inc
05/02/20247:35AMPR Newswire (US)Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024NASDAQ:PAVMPAVmed Inc
05/02/20246:49AMPR Newswire (US)Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer TestingNASDAQ:PAVMPAVmed Inc
04/30/20246:35AMPR Newswire (US)PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstituteNASDAQ:PAVMPAVmed Inc
04/29/20247:47AMPR Newswire (US)Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness MonthNASDAQ:PAVMPAVmed Inc
04/08/20247:30AMPR Newswire (US)Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:PAVMPAVmed Inc
 Showing the most relevant articles for your search:NASDAQ:PAVM

Your Recent History

LSE
19NG
Cred Ag Co 26
LSE
BA60
07jun2027c
LSE
UZ21
Citi Fun 25
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved